Pidilizumab, CAS 1036730-42-3

Product Description: Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77./[2]Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462.

CAS Number: 1036730-42-3

Molecular Weight: N/A

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: PD-1/PD-L1

• Artikelnummer: MEXHY-P990077-0
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P990077-0
• Green Labware: Nein
• Verpackungseinheit: Get quote
• Mengeneinheit: STK